证券代码：300869 证券简称：康泰医学 公告编号：2025-067 债券代码：123151 债券简称：康医转债 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2025 年 9 月 15 日（周一）15:00-17:00。 届时公司董事、总经理杨志山先生，副总经理、董事会秘书、财务总监郑敏 女士将在线就公司治理、发展战略、经营状况和可持续发展等投资者关心的问 题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 康泰医学系统(秦皇岛)股份有限公司董事会 康泰医学系统（秦皇岛）股份有限公司 关于参加 2025 年河北辖区上市公司投资者网上集体接待日 暨 2025 年半年报集体业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，康泰医学系统(秦皇岛)股份有限公司 （以下简称"公司"）将参加由河北省上市公司协会与深圳市全景网络有限公司 联合举办的"2025 年河北辖区 ...

Core Viewpoint - Kangtai Medical (300869.SZ) announced a significant reduction in shareholding by shareholder Wang Guili, indicating a potential shift in investor sentiment and ownership structure [1] Summary by Categories Shareholding Reduction - Wang Guili reduced her shareholding by a total of 5,109,700 shares, which accounts for 1.27% of the company's total share capital [1] - The reduction occurred through two methods: 2,120,700 shares were sold via centralized bidding (0.53% of total shares) and 2,989,000 shares through block trading (0.74% of total shares) [1] - Following the reduction, Wang Guili's holdings decreased from 47,126,226 shares to 42,016,526 shares, representing a drop in ownership from 11.73% to 10.46% of the total share capital [1]

Core Viewpoint - 康泰医学 announced a significant reduction in shareholding by shareholder 王桂丽, indicating a potential shift in investor sentiment and ownership structure [1] Summary by Categories Shareholding Changes - 王桂丽 reduced her shareholding through two methods: selling 2,120,700 shares (0.53% of total shares) via centralized bidding and 2,989,000 shares (0.74% of total shares) through block trading [1] - The total shares sold amounted to 5,109,700 shares, representing 1.27% of the company's total share capital [1] - Following the reduction, 王桂丽's holdings decreased from 47,126,226 shares to 42,016,526 shares, changing her ownership percentage from 11.73% to 10.46% [1]

证券代码：300869 证券简称：康泰医学 公告编号：2025-066 债券代码：123151 债券简称：康医转债 | 1.基本情况 | | | --- | --- | | 信息披露义务人 | 王桂丽 | | 住所 | 河北省秦皇岛市海港区****** | | 权益变动时间 | 2025年9月1日至2025年9月9日 | | 权益变动过程 | 王桂丽女士因自身资金需求，于2025年9月1日至2025年9月9日通过集中竞 | | | | | --- | --- | --- | --- | --- | | | 价方式减持公司股份2,120,700股（占公司目前总股本的0.53%），通过大 | | | | | | 宗交易方式减持公司股份2,989,000股（占公司目前总股本的0.74%），累 | | | | | | 计减持所持公司股份5,109,700股(占公司目前总股本的1.27%)。本次权益 | | | | | | 变动不会导致公司控制权发生变更，不会对公司治理结构、股权结构及持 | | | | | | 续性生产经营产生影响。 | | | | | 康泰医学 股票简称 | 300869 | 股票代码 | | | ...

Core Viewpoint - 康泰医学 has accelerated the development and market application of new technologies and products since 2025, adjusting marketing strategies and promoting globalization, leading to steady growth in both domestic and international business [1] Group 1: Financial Performance - In the first half of 2025, 康泰医学 achieved operating revenue of 217.55 million yuan, a year-on-year increase of 2.72% [1] - The net profit attributable to shareholders reached 16.94 million yuan, a significant increase of 107.39% compared to the same period last year [1] - The net profit after deducting non-recurring items was 12.45 million yuan, showing a substantial growth of 423.17% year-on-year [1] Group 2: Market Drivers - The growth in performance is driven by three main factors: the acceleration of population aging and the trend of home healthcare, which has increased market demand and customer purchasing willingness [1] - The company maintains a high level of R&D investment, successfully launching new products such as zirconia blocks, blood glucose meters, and in vitro diagnostic reagents, which meet emerging market demands [1] - The implementation of globalization and localization strategies has enhanced market development efforts, leading to steady growth in regions such as Southeast Asia, Eastern Europe, and South America [1] Group 3: R&D Investment - R&D innovation is key to maintaining competitiveness, with the company investing 46.48 million yuan in R&D in the first half of the year [2] - The company added 61 domestic patents during the reporting period, including 3 invention patents, 22 utility model patents, and 36 design patents, along with 117 software copyrights [2] - As of the end of the reporting period, the company and its subsidiaries held a total of 484 valid domestic and international patents and 369 software copyrights, indicating a strong technological reserve [2]

证券代码：300869 证券简称：康泰医学 公告编号：2025-065 债券代码：123151 债券简称：康医转债 | 注册证编号 | 冀械注准 20232060358 | | --- | --- | | 产品名称 | 彩色多普勒超声诊断系统 | | | 1、规格型号: | | | "CMS1700A、CMS1700B"变更为"CMS1700A、CMS1700B、CMS1700C" | | | 2、产品技术要求：升级新标准：GB 9706.1-2007 变更为 GB | | 变更内容 | 9706.1-2020、YY 0505-2012 变更为 YY 9706.102-2021，并增加软 | | | 件功能、GB 9706.237-2020 医用电气设备 第 2-37 部分：超声诊断 | | | 和监护设备的基本安全和基本性能专用要求等。 | 本次变更通过新增产品型号、升级技术标准，更好的契合了市场需求，有助于 增强公司市场竞争力，拓宽业务覆盖范围，对公司长期发展产生积极作用。产品的 实际销售情况取决于未来市场推广效果，目前尚无法预测其对公司未来经营业绩的 影响。敬请投资者注意投资风险。 特此公告。 康泰医学 ...

Investment Rating - The report provides a positive outlook on the MASH non-invasive diagnosis technology, suggesting it could accelerate new drug development in the pharmaceutical and biotechnology sector [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.65% from August 25 to August 29, underperforming compared to the Wind All A index (1.9%) and the CSI 300 index (2.71%). Only the medical research outsourcing (4.9%) and other biological products (0.14%) sectors saw gains, while in vitro diagnostics (-4.12%), raw materials (-3.34%), and vaccines (-0.59%) faced significant declines [2][7]. - The FDA has accepted the proposal for using VCTE-LSM as a reasonable alternative endpoint for clinical trials in adults with MASH and moderate to advanced fibrosis. This non-invasive method is expected to enhance patient compliance and could lead to a surge in drug development in the MASH area within the next two to three years [2][13]. - The report emphasizes the potential for domestic companies in China to leverage their cost advantages and forward-looking strategies in the field of non-invasive companion diagnostics, particularly in the MASH drug development competition [2]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance was notably weaker than the broader market indices, with specific sub-sectors like medical research outsourcing and other biological products showing resilience [7][8]. - Individual stocks such as Tianchen Medical (30.1%), Ailis (25.6%), and Maiwei Biotech-U (22.4%) performed well, while stocks like Lifang Pharmaceutical (-13.9%), Yuekang Pharmaceutical (-11.9%), and Kanghua Biotech (-11.1%) faced significant losses [10][12]. Industry News and Key Company Announcements - On August 28, Kangfang Biotech announced that its drug AK112 received approval for treating advanced non-squamous non-small cell lung cancer, with promising clinical trial results expected to be presented at an international conference [12]. - The report highlights various companies' financial performances, with notable revenue changes and profit margins, indicating a mixed outlook across the sector [16][17].

Core Insights - 康泰医学 reported a total revenue of 218 million yuan for the first half of 2025, representing a year-on-year increase of 2.72% [1] - The net profit attributable to shareholders reached 16.94 million yuan, a significant increase of 107.39% compared to the previous year [1] - The company's gross margin improved by 22.06% to 60.42%, while the net margin increased by 101.9% to 7.79% [1] Financial Performance - Total revenue for 2025 was 218 million yuan, up from 212 million yuan in 2024, marking a 2.72% increase [1] - Net profit attributable to shareholders rose from 8.17 million yuan in 2024 to 16.94 million yuan in 2025, a growth of 107.39% [1] - The company reported a significant increase in non-recurring net profit, from a loss of 3.85 million yuan to a profit of 12.45 million yuan, reflecting a 423.17% improvement [1] - Cash and cash equivalents increased by 44.95% to 737 million yuan [1] - Accounts receivable decreased by 7.55% to 39.60 million yuan [1] - Interest-bearing liabilities rose by 12.80% to 906 million yuan [1] Profitability Metrics - Gross margin improved to 60.42%, up from 49.50% in the previous year, an increase of 22.06% [1] - Net margin increased from 3.86% to 7.79%, a growth of 101.90% [1] - Total selling, administrative, and financial expenses amounted to 54.90 million yuan, accounting for 25.23% of revenue, which is a 17.65% increase year-on-year [1] - Earnings per share doubled from 0.02 yuan to 0.04 yuan, reflecting a 100% increase [1] - Operating cash flow per share increased by 86.78% from 0.03 yuan to 0.06 yuan [1] Debt and Financial Health - The company maintains a healthy cash position, with cash assets reported as very strong [4] - The interest-bearing debt ratio has reached 32.74%, indicating a need for attention regarding the company's debt situation [5]

Core Insights - 康泰医学 reported a total revenue of 218 million yuan for the first half of 2025, ranking 83rd among disclosed peers [1] - The company's net profit attributable to shareholders was 16.94 million yuan, ranking 76th among disclosed peers [1] - Operating cash flow was 25.90 million yuan, ranking 72nd among disclosed peers [1] Financial Performance - The latest debt-to-asset ratio is 35.93%, ranking 94th among disclosed peers, with an increase of 3.16 percentage points from the previous quarter and 4.10 percentage points from the same period last year [1] - The latest gross profit margin is 60.42% [1] - The latest return on equity (ROE) is 0.95%, ranking 84th among disclosed peers [1] Earnings and Ratios - The diluted earnings per share is 0.04 yuan, ranking 91st among disclosed peers [2] - The total asset turnover ratio is 0.08 times, ranking 104th among disclosed peers [2] - The inventory turnover ratio is 0.31 times, ranking 113th among disclosed peers [2] Shareholder Structure - The number of shareholders is 31,100, with the top ten shareholders holding 238 million shares, accounting for 59.35% of the total share capital [2] - The largest shareholder, 胡坤, holds 43.85% of the shares [2] - Other significant shareholders include 壬桂丽 (11.73%) and 香港中央结算有限公司 (0.93%) [2]

Group 1 - The company has not declared any cash dividends, stock bonuses, or capital reserve transfers during the reporting period [3] - There has been no change in the controlling shareholder or actual controller during the reporting period [4] - The company does not have any preferred shareholders or related holdings during the reporting period [4] Group 2 - All directors attended the board meeting to review the report [2] - The company does not require retrospective adjustments or restatements of previous accounting data [3] - The company has no outstanding bonds as of the report date [4]